ReviewAdvances in therapy2019
Management of Fibrosing Interstitial Lung Diseases.
Review in Advances in therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Biomarker profiles in idiopathic and progressive pulmonary fibrosis after LPARespiratory research · 2026Trial
- Holistic Management of Pulmonary Fibrosis: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
- Systemic autoimmune rheumatic diseases-associated interstitial lung disease: a pulmonologist's perspective.Breathe (Sheffield, England) · 2025Review
- Retrospective Analysis of Predictive Biomarkers of Survival in Acute Exacerbation of Fibrosing Interstitial Lung Disease: A Single-Center Study in Spain.Journal of clinical medicine · 2025Article
- Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease.Arthritis research & therapy · 2025Article
- The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions.American journal of respiratory and critical care medicine · 2024Article
- Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease.Biomedicines · 2024Review
- Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention.Life (Basel, Switzerland) · 2024Review
- Antifibrotic treatment response comparison of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.Turkish journal of medical sciences · 2024Article
- Airway soluble CSF1R predicts progression in patients with idiopathic pulmonary fibrosis.ERJ open research · 2023Article
- Immune-mediated lung diseases: A narrative review.Frontiers in medicine · 2023Review
- Pharmacological approaches to pulmonary fibrosis following COVID-19.Frontiers in pharmacology · 2023Review
- Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.Annals of the American Thoracic Society · 2022Article
- Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.BMC pulmonary medicine · 2022Article
- Treating Autoimmune-Related Interstitial Lung Disease With B Cell Depletion.Frontiers in medicine · 2022Review
- Management and support of patients with fibrosing interstitial lung diseases.The Nurse practitioner · 2021Article
- Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- MCTR1 Intervention Reverses Experimental Lung Fibrosis in Mice.Journal of inflammation research · 2021Article
- Immunoregulatory Property of C-Type Lectin-Like Receptors in Fibrosing Interstitial Lung Diseases.International journal of molecular sciences · 2020Review
- CaBritish journal of pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A proportion of patients with interstitial lung diseases (ILDs), including the ILDs that are commonly associated with autoimmune diseases, develop a progressive fibrosing phenotype characterised by worsening of lung function, dyspnoea and quality of life, and early mortality. No drugs are approved for the treatment of ILDs other than idiopathic pulmonary fibrosis (IPF). At present, immunomodulatory medications are the mainstay of treatment for non-IPF ILDs. However, with the exception of systemic sclerosis-associated ILD, the evidence to suggest that immunosuppression may preserve lung function in patients with these ILDs comes only from retrospective, observational, or uncontrolled studies. In this article, we review the evidence for the treatments currently used to treat ILDs associated with autoimmune diseases and other ILDs and the ongoing trials of immunosuppressant and antifibrotic therapies in patients with these ILDs.Funding: Boehringer Ingelheim.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.